Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.

Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU.

Acta Ophthalmol Scand. 2006 Aug;84(4):556-7. No abstract available.

2.

Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.

dell'Omo R, Kulkarni A, Franks WA.

Acta Ophthalmol. 2008 Sep;86(6):698-700. No abstract available.

3.

Regression of neovascular iris vessels by intravitreal injection of bevacizumab.

Mason JO 3rd, Albert MA Jr, Mays A, Vail R.

Retina. 2006 Sep;26(7):839-41. No abstract available.

PMID:
16963866
4.

Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.

Saito Y, Higashide T, Takeda H, Murotani E, Ohkubo S, Sugiyama K.

Am J Ophthalmol. 2010 Jun;149(6):964-972.e1. doi: 10.1016/j.ajo.2010.01.008. Epub 2010 Apr 9.

PMID:
20381786
5.

Intravitreal bevacizumab in a patient with neovascular glaucoma.

Kahook MY, Schuman JS, Noecker RJ.

Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):144-6.

PMID:
16583637
6.

Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.

Lupinacci AP, Calzada JI, Rafieetery M, Charles S, Netland PA.

Adv Ther. 2009 Feb;26(2):208-16. doi: 10.1007/s12325-009-0001-1. Epub 2009 Feb 20.

PMID:
19234680
7.

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

Avery RL.

Retina. 2006 Mar;26(3):352-4. No abstract available.

PMID:
16508438
8.

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Yazdani S, Hendi K, Pakravan M.

J Glaucoma. 2007 Aug;16(5):437-9.

PMID:
17700285
9.

Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y.

Ophthalmology. 2008 Sep;115(9):1571-80, 1580.e1-3. doi: 10.1016/j.ophtha.2008.02.026. Epub 2008 Apr 28.

PMID:
18440643
10.

[Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases].

Douat J, Auriol S, Mahieu-Durringer L, Ancèle E, Pagot-Mathis V, Mathis A.

J Fr Ophtalmol. 2009 Nov;32(9):652-63. doi: 10.1016/j.jfo.2009.10.001. Epub 2009 Nov 4. French.

11.

Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.

Jiang Y, Liang X, Li X, Tao Y, Wang K.

Acta Ophthalmol. 2009 Nov;87(7):736-40. doi: 10.1111/j.1755-3768.2008.01353.x. Epub 2008 Sep 18.

12.

Intracameral bevacizumab for iris rubeosis.

Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group.

Am J Ophthalmol. 2006 Jul;142(1):158-60.

PMID:
16815268
13.
14.

Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.

Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N.

Arch Ophthalmol. 2010 Dec;128(12):1539-45. doi: 10.1001/archophthalmol.2010.282.

PMID:
21149776
15.

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.

Davidorf FH, Mouser JG, Derick RJ.

Retina. 2006 Mar;26(3):354-6. No abstract available.

PMID:
16508439
17.

Bevacizumab (Avastin) for the treatment of neovascular glaucoma.

Chilov MN, Grigg JR, Playfair TJ.

Clin Exp Ophthalmol. 2007 Jul;35(5):494-6.

PMID:
17651259
18.

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A.

Ophthalmology. 2006 Oct;113(10):1695.e1-15.

PMID:
17011951
19.

Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.

Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W.

Retina. 2008 May;28(5):696-702. doi: 10.1097/IAE.0b013e3181679c0b.

PMID:
18463512
20.

Regression of neovascular posterior capsule vessels by intravitreal bevacizumab.

Eren E, Küçükerdönmez C, Yilmaz G, Akova YA.

J Cataract Refract Surg. 2007 Jun;33(6):1113-5.

PMID:
17531712

Supplemental Content

Support Center